

RESEARCH ARTICLE

Estimation of A₂ subgroup in A and AB blood groups of human blood and its clinical significance

Vivek Deepak S D¹, Dr. Subhasish Das²¹M.sc MLT Sri Devaraj URS Medical College Tamaka, Kolar-563101 Karnataka, India² M.D, Ph.D. Sri Devaraj URS Medical College Tamaka, Kolar-56 Karnataka, India*Corresponding Author
Dr. Subhasish Das

Article History

Received: 21.07.2025

Revised: 25.08.2025

Accepted: 17.09.2025

Published: 03.10.2025

Abstract: **BACKGROUND:** The clinical implications of anti A₁ antibodies in individuals with A₂ and A₂B blood types remain a subject of debate. Although rare, a few case reports have documented clinically significant anti A₁ antibodies that react at 37 °C and lead to haemolysis of donor red blood cells. This study therefore seeks to determine both the prevalence of the A₂ and A₂B subgroups and the clinical relevance of anti A₁ antibodies within these populations. **MATERIALS AND METHODS:** This cross-sectional observational study that was conducted at the RL Jalappa Blood Bank Centre. Blood group determination and differentiation between A₁ and A₂ subgroups. Blood group determination and differentiation between A₁ and A₂ subgroups was performed using the gold-standard test Column technology, based on the agglutination reaction with anti-A₁ lectin. Serum samples from individuals with A₂ and A₂B subgroups was tested using A₁ red cells to confirm the presence of anti-A₁ antibodies. Further analysis was conducted to identify the type of anti-A₁ antibody—whether IgM or IgG—and assess its clinical significance. **RESULTS:** A total of 4,000 blood samples from individuals with A and AB blood groups—comprising both patients and donors—were analysed. Among these, 3,150 were blood group A and 850 were group AB. Within the A group, 3,070 were subtype A₁ and 80 were A₂, while AB participants included 820 A₁B and 30 A₂B individuals. Out of 3,000 donors, the prevalence of subgroups was 98.7% A₁, 1.3% A₂, 94.1% A₁B, and 2.9% A₂B. In the cohort of 1,000 patients, A₁ and A₂ accounted for 93.8% and 6.2%, respectively, while A₁B and A₂B represented 92.1% and 7.9%, respectively. No anti A₁ antibodies were detected in the serum of A₂ individuals, either donors or patients; similarly, none of the A₂B donors or patients exhibited anti A₁ antibodies. These antibodies showed no clinical significance, as they did not cause agglutination at 37 °C. **CONCLUSIONS:** To date, no investigations from Southern Indian state of Karnataka have explored the prevalence of A₂ and A₂B subgroups and the presence of anti A₁ antibodies in both donor and patient populations. Our study indicates that routine screening for anti A₁ antibodies in individuals with A₂ or A₂B subgroups is a good practice. However, in transplantation settings, it remains mandatory to subtype A and AB blood groups and specifically check for anti A₁ antibodies.

Keywords: ABH blood group, Anti-A₁ lectin, blood Group A, AB

INTRODUCTION

More than a century after the discovery of the ABO blood group system, immunohematology still encounters challenges when identifying ABO subtypes and weaker antigen variants. The antigenic properties of the ABO blood groups stem from specific carbohydrate structures displayed on the surface of red blood cells—structures that also occur in epithelial cells, vascular endothelial cells, and platelets.^[1] Due to polymorphisms in the ABO genes, reduced expression of A or B antigens occurs on red blood cells, giving rise to A and AB subgroups. The two most common subgroups, A₁ and A₂, are distinguished both quantitatively—A₁ cells carry significantly more antigen sites than A₂—and qualitatively, with distinct antigen structures.^[2] Both A₁ and A₂ red cells exhibit strong agglutination with monoclonal anti-A reagents. However, they can be differentiated serologically using lectin derived from *Dolichos biflorus* (anti-A₁ lectin), which agglutinates only A₁ cells—thus distinguishing the A₁ and A₂ subgroups.

The *Dolichos biflorus* lectin agglutinates only A₁ red cells and does not affect A₂ cells. Studies in India reveal that within blood group A, A₁ and A₂ subgroups occur

at frequencies of approximately 98.14% and 1.07%, respectively; among AB individuals, A₁B and A₂B subgroups are found in about 89.28% and 8.99%, respectively.^[3] Anti-A₁ antibodies frequently manifest as atypical cold agglutinins—reacting at room temperature—and are sometimes detected in the serum of A₂ individuals. These IgM-type antibodies bind red cells under cooler conditions, though they typically have diminished or no activity at 37 °C or Anti-A₁ antibodies often present as atypical cold agglutinins, reacting at room temperature, and are sometimes detected in the serum of A₂ or A₂B individuals who do not express the A₁ antigen.^[4]

Only around **0.4 %** of individuals with an A₂ blood group—and **25 %** of those with A₂B—harbour anti-A₁ antibodies in their serum, which may become clinically significant if they react at 37 °C, potentially causing haemolysis of A₁ red cells.^[4-6]

Adult A₁ red cells carry approximately **0.8 × 10⁶** antigen sites per cell, whereas adult A₂ cells have about **0.24 × 10⁶**, a level similar to that found in A₁ neonatal cells, which range between **0.25–0.37 × 10⁶** sites per cell. New born red cells may show little to no reaction—or only weak agglutination—with anti-A₁

reagents, due to their underdeveloped antigen expression at birth^[7] In southern part of India, only a handful of studies have examined the prevalence of A₁ and A₂ subgroups among blood donors, with few involving patients. To address this gap, our study aimed to determine the prevalence of A₁ and A₂ subgroups—as well as anti-A₁ antibodies within both donor and patient populations for A and AB blood groups, and to evaluate whether any of these antibodies exhibit clinical significance.

Objectives:

The present study was taken up with the following aims and objectives

- To assess the distribution of blood subgroups A₁, A₂, A₁B, and A₂B among the population in Kolar District, Karnataka, India.
- To investigate the clinical significance of these blood subgroups in medical practice.

Materials and Methods:

This cross-sectional observational study was conducted at the RL Jalappa Blood Bank Centre. Blood group determination and differentiation between A₁ and A₂ subgroups was performed using the gold-standard test Column technology, based on the agglutination reaction with anti-A₁ lectin. Serum samples from individuals with A₂ and A₂B subgroups was tested using A₁ red cells to confirm the presence of anti-A₁ antibodies. Further analysis was conducted to identify the type of anti-A₁ antibody—whether IgM or IgG—and assess its clinical significance.

Sample size calculation will be based on the following parameters:

Margin of error (MOE): 9.6%

- **Expected distribution proportion (p):** 30% of the blood donor population
- **Confidence interval:** 95%
- **Software used:** OpenEpi Info

The sample size (n) will be calculated using the formula:

$$n = \frac{N \times X \times X + N - 1}{n} = \frac{N \times X \times X}{X + N - 1}$$

Where:

$$X = Z_{\alpha/2} \times p \times (1 - p) \text{ MOE}^2 \quad X = \frac{Z_{\alpha/2}^2 \times p \times (1 - p)}{\text{MOE}^2}$$

Here, $Z_{\alpha/2} = 1.96$, $Z_{\alpha/2} = 1.96$, corresponding to a 95% confidence level. p is the estimated sample proportion, and N is the total population size.

A total of **4000** samples comprising 3000 eligible donors and 1000 patients was included in the study.

Inclusion Criteria

- Donors who meet the eligibility requirements as per the Drugs and Cosmetics Act.
- Individuals who have provided written informed consent.
- Patients with blood groups A and AB.

Exclusion Criteria

- Donors with irregular red cell antibodies.
- Sero positive donors.
- Donors and patients who have not provided consent.
- Patients of other blood groups.
- Neonates.

Page 5

Study Procedure

This is Cross sectional observational study was conducted at RL Jalappa blood bank centre. From March 2023 to March 2025 which is a tertiary care centre of South Eastern state of Karnataka, India. A total of 4000 blood samples of both donors and patients of A and AB blood groups were included in our study. Thirty-two blood samples of the neonate with four A₂ and three A₂B were excluded from the study. This is because ABO antigens are not fully developed at birth, and red cells of neonates of the A₁ blood group may not react or react weakly with anti-A₁.


RESULT:

Study Protocol

Performance of blood grouping among the donors and the patients

Estimation of A and AB blood samples of the donors and patients
With anti- A₁lectin





Flowchart 1: Determination of A₁ and A₂ and significance of anti-A₁ antibody Page 6

A total of 4000 blood samples from individuals with A and AB blood groups—comprising both patients and donors—were analysed. Among these, 3,150 were blood group A and 850 were group AB. Within the A group, 3,070 were subtype A₁ and 80 were A₂, while AB participants included 820 A₁B and 30 A₂B individuals (see Table 1). Out of 3,000 donors, the prevalence of subgroups was 98.7% A₁, 1.3% A₂, 94.1% A₁B, and 2.9% A₂B. In the cohort of 1,000 patients, A₁ and A₂ accounted for 93.8% and 6.2%, respectively, while A₁B and A₂B represented 92.1% and 7.9%, respectively.

No anti-A₁ antibodies were detected in the serum of A₂ individuals, either donors or patients; similarly, none of the A₂B donors or patients exhibited anti-A₁ antibodies. These antibodies showed no clinical significance, as they did not cause agglutination at 37 °C (see Table 2).

DISCUSSIONS

The A and AB blood groups can be further classified into major subgroups, such as A₁ and A₂. These subgroups react similarly with monoclonal anti-A reagents; however, distinguishing between them requires the use of anti-A₁ lectin, derived from *Dolichos biflorus* seeds. In this study, the prevalence of the A₂ subgroup was found to be (2.6%) and (3.6%) among individuals with blood group A and among those with blood group AB. These findings are consistent with a previous study conducted in South India by Shamee S et al.^[4] Other research has reported the prevalence of A₂ and A₂B among blood donors to range between 4.1%–5.8% and 19.2%–31.5%, respectively.^[8,9] In the current study, the distribution of A₁ and A₂ within the A blood group closely aligned with results from Giriyan et al., whereas the prevalence of A₁B and A₂B within the AB

group was slightly higher.^[10] This increased prevalence of the A₂B subgroup compared to A₂ may be attributed to the suppressive effect of a strong B gene on A₁ antigen expression.^[11]

In our study population, the prevalence of A₁ and A₂ subgroups was nearly identical among both donors and patients. Individuals with the A₂B phenotype are more likely to produce anti-A₁ antibodies than those with the A₂ phenotype, due to the relatively lower expression of A antigens on A₂B red blood cells.^[12] In this study, there is no anti-A₁ antibodies were detected in A₂ blood group donor or patients similarly with A₂b blood group donor and patients^[4] The higher incidence of anti-A₁ in A₂B individuals has a genetic basis—specifically, the presence of the *R101 allele, found in 41% of A₂B individuals compared to only 1% of those with A₂.

^[1]This allele appears in A₁ (*R101/*O) and A₂ (*R101/*B) individuals as a heterozygous combination with either the O or B allele. The presence of anti-A₁ antibodies in A₂ and A₂B individuals can sometimes lead to blood group discrepancies, primarily during reverse typing. ^[1] In our study, such discrepancies were observed in three A₂B patients, while none of the A₂ individuals exhibited anti-A₁ antibodies. ^[14] These discrepancies are typically resolved using pooled A₂ cells instead of A₁ cells during reverse typing.

Anti-A₁ antibodies are usually cold-reacting and agglutinate at room temperature; however, in rare cases, they may react at 37°C and cause significant haemolysis of A₁ cells. ^[15,16] Therefore, testing with anti-A₁ lectin is only necessary in patients who show incompatible crossmatches during the anti-human globulin (AHG) phase. If anti-A₁ antibodies are clinically significant, A₂ recipients should receive either A₂ or O blood, and A₂B recipients should be transfused with AHG-compatible red cells from group A₂B, B, A₂, or O. ^[6, 14, and 17]

As our study did not identify any clinically significant anti-A₁ antibodies in either A₂ or A₂B individuals, routine testing for A₁/A₂ subgroups or anti-A₁ antibodies appears to have limited relevance in this population. This aligns with conclusions from other studies suggesting that in resource-limited settings like India, routine A and AB subgrouping is not recommended. ^[18] After A₁, A₂ is the next most common A subgroup, with approximate prevalence of 80% and 20%, respectively. Other subgroups, such as A₃ and A₄, are extremely rare, occurring in approximately 1

in 14,448 and 1 in 43,344 individuals, respectively. A₃ subgroups are typically identified serologically as large...

A₃ subgroups are serologically identified by the presence of large agglutinates resembling a cluster of grapes, seen against a background of numerous unagglutinated cells—a pattern known as mixed field appearance. ^[2] In our study, we did not observe any A subgroups exhibiting this mixed field pattern, indicating the rarity of such subgroups in our population.

Several studies have reported successful kidney transplants from A₂ blood donors to recipients with blood groups O and B. Therefore, subtyping of blood group A can play a crucial role in optimizing the use of A₂ donors for renal transplantation in patients with O and B blood types. ^[19] Additionally, subtyping is valuable in managing platelet inventories, as platelets from A₂ and A₂B donors can be safely transfused to O and B group recipients, respectively, with favourable post-transfusion recovery and corrected count increments. ^[20]

However, it is important to perform subtyping of group A in specific critical situations—for instance, in cases involving weak subgroups of A that are negative for anti-A₁ lectin, or in incompatible solid organ transplants. ^[21] There have been reports of hyper acute rejection of A subgroup renal grafts in O group recipients, highlighting the importance of accurate subtyping in such contexts. ^[22]

CONCLUSION

To date, no investigations from Southern Indian state of Karnataka have explored the prevalence of A₂ and A₂B subgroups and the presence of anti-A₁ antibodies in both donor and patient populations. Our study indicates that routine screening for anti-A₁ antibodies in individuals with A₂ or A₂B subgroups is a good practice. However, in transplantation settings, it remains mandatory to subtype A and AB blood groups and specifically check for anti-A₁ antibodies. ^[3]

As it is already standard practice, ABO and Rh blood typing—with subgrouping—should be performed in every case to minimize transfusion-related complications. Additional studies across different regions of the state are needed to better understand the distribution of ABO, Rh blood groups, and their subgroups. This information will also help blood banks anticipate demand for specific blood types and subtypes. ^[4]

Blood Group	Sub Group	Patients,n(%)	Donor,n(%)	Total,n(%)
A	A ₁	800(93.8)	2270(98.7)	3070(97.4)
	A ₂	50(6.2)	30(1.3)	80(2.6)
AB	A ₁ B	140(92.9)	680(97.1)	820(96.4)
	A ₂ B	10 (7.1)	20(2.9)	30(3.6)

Table 1: Prevalence of A₂ and A₂B subgroups among A and AB blood groups (n=4000, A=3150, AB=850). A total of 4000 blood samples from individuals with A and AB blood groups—including both patients and donors—were analysed.

Among the A group samples, 3070 were classified as A₁ and 380 as A₂. In the AB group, 820 were A₁B and 30 were A₂B.

Table 2: Prevalence of anti-A₁ antibody in A₂ and A₂B subgroups: The anti-A₁ antibodies were considered clinically insignificant as they did not exhibit agglutination at 37°C.

A ₂ sub groups (n=37)		A ₂ b Sub groups (n=34)	
Donors	Patients	Donors	Patients
Presence of anti-A ₁ antibody	Nil	Nil	Nil

REFERENCES

1. Storry JR, Olsson ML. The ABO blood group system revisited: A review and update. *Immunohematology* 2009;25:48-59.
2. Thakral B, Saluja K, Bajpai M, Sharma RR, Marwaha N. Importance of weak ABO subgroups. *Lab Med* 2005;36:32-4.
3. Elnour MA, Ali NY, Mohammed HA, Hummeda SA, Alshazally WY, Elderderly AY. Frequency of the A2-subgroup among blood group A and blood group AB among students of faculty of medicine and health sciences at Alimam Almahadi university, White Nile, Sudan. *Hematol Transfus Int J* 2016;1:104-6. DOI: 10.15406/htij.2016.01.00022.
4. Shastri S, Bhat S. Imbalance in A₂ and A₂B phenotype frequency of ABO group in South India. *Blood Transfus* 2010;8:267-70.
5. Rudmann SV. Textbook of Blood Banking and Transfusion Medicine. 1st ed. USA: WB Saunders; 1995. p. 73-5.
6. Shah K, Delvadia B. The not so insignificant anti-A₁ antibody: Cause of severe hemolytic transfusion reaction. *Am J Clin Pathol* 2018;149 Suppl 1:159.
7. Klein GH, Anstee DJ. Mollison's Blood Transfusion in Clinical Medicine. 11th ed. Oxford: Wiley-Blackwell; 2006. p. 114-9.
8. Mahapatra S, Mishra D, Sahoo D, Sahoo BB. Study of prevalence of A₂, A₂B along with major ABO blood groups to minimize the transfusion reactions. *Int J Sci Res* 2016;5:189-90.
9. Chaitanya Kumar IS, Yashovardhan A, Suresh Babu B, Verma A, Sreedhar Babu KV, Jothi Bai DS. The prevalence of A₂ and A₂B subgroups in blood donors at a tertiary care teaching hospital blood bank of Rayalaseema region: A pilot study. *J Clin Sci Res* 2012;1:50.
10. Giriyan SS, Agrawal A, Bajpai R, Nirala NK. A₁ and A₂ Sub-types of blood group 'A': A reflection of their prevalence in North Karnataka Region. *J Clin Diagn Res* 2017;11:40-2.
11. Voak D, Lodge TW, Reed JV. A possible explanation for the expression of A₂B phenotypes observed in some populations. *Vox Sang* 1970;18:471-4.
12. Hosseini-Maaf B, Hellberg A, Rodrigues MJ, Chester MA, Olsson ML. ABO exon and intron analysis in individuals with the AweakB phenotype reveals a novel O1v-A2 hybrid allele that causes four missense mutations in the A transferase. *BMC Genet* 2003;4:17.
13. Page 13
14. Ogasawara K, Yabe R, Uchikawa M, Bannai M, Nakata K, Takenaka M, et al. Different alleles cause an imbalance in A₂ and A₂B phenotypes of the ABO blood group. *Vox Sang* 1998;74:242-7.
15. Cooling L. ABO, H and Lewis structurally related antigens. In: Fung M, Grossman B, Hillyer C, Westhoff C, editors. Technical Manual. 18th ed. Bethesda: AABB; 2018. p. 295-7.
16. Helmich F, Baas I, Ligthart P, Bosch M, Jonkers F, de Haas M, et al. Acute hemolytic transfusion reaction due to a warm reactive anti-A (1). *Transfusion* 2018;58:1163-70.
17. Preece J, Magrin G, Webb A, Akers C, Davis A. Transfusion medicine illustrated. A bloody mistake: Unrecognized warm reactive anti-A₁ resulting in acute hemolytic transfusion reaction. *Transfusion* 2011;51:914-5.
18. Guidelines for Pretransfusion Laboratory Practice. Version: 5th ed. Australian and New Zealand Society of Blood Transfusion. Available from: https://www.anzsbt.org.au/data/documents/guidelines/PLP_Guidelines_Mar07.pdf. [Last accessed on 2019 Jul 16].
19. Hazarika R, Basu S, Kaur P. Subgrouping of A and AB blood groups in Indian blood centres: Is it required? *J Indian Med Assoc* 2011;109:561-2.
20. Sorensen JB, Grant WJ, Belnap LP, Stinson J, Fuller TC. Transplantation of ABO group A₂ kidneys from living donors into group O and B recipients. *Am J Transplant* 2001;1:296-9.
21. Redfield RR, Parsons RF, Rodriguez E, Mustafa M, Cassuto J, Vivek K, et al. Underutilization of A₂ ABO incompatible kidney transplantation. *Clin Transplant* 2012;26:489-94.

22. O'Donoghue D, Kelley W, Klein HG, Flegel WA. Recommendations for transfusion in ABO-incompatible hematopoietic stem cell transplantation. *Transfusion* 2012;52:456-8.
23. Sachan D. Blood group A(int) causing uncertainty during organ donor work-up for incompatible (A2-O) liver transplantation. *Blood Transfus* 2013;11:460-1.